Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 17, 1998

Primary Completion Date

April 19, 2000

Study Completion Date

May 27, 2003

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)

cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ludwig Institute for Cancer Research

OTHER